“Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion” (2019) SKIN The Journal of Cutaneous Medicine, 3, p. S31. doi:10.25251/skin.3.supp.31.